Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2017 · 10-Q
Revenue—
Net Income-$75.63K-$75.63KN/M vs Q1 2016 EPS Diluted-$0.01-$0.01N/M vs Q1 2016 Operating Income-$233,940— Operating Cash Flow-$1,598N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,480— ended Mar 31, 2017 · filed Oct 4, 2017 · 187 d after period end